Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2008 February;60(1) > Minerva Ginecologica 2008 February;60(1):77-82

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  POLYCISTIC OVARY SYNDROME


Minerva Ginecologica 2008 February;60(1):77-82

language: English

Role of metformin in patients with polycystic ovary syndrome: the state of the art

Palomba S. 1, Falbo A. 1, Russo T. 1, Orio F. 2, Tollino A. 3, Zullo F. 1

1 Department of Gynecology and Obstetrics, Magna Graecia University of Catanzaro, Catanzaro, Italy
2 Endocrinology, Parthenope University of Naples, Naples, Italy
3 Department of Gynecology and Obstetrics, Parthenope University of Naples, Naples, Italy


PDF  


Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS). The aim of the current review was to evaluate the current role of metformin in the treatment of the PCOS-related disorders. The Authors analyze here the administration of metformin for treating the ovarian dysfunction due to PCOS, and show the evidences available in literature regarding its alternative uses.

top of page

Publication History

Cite this article as

Corresponding author e-mail